Loading stock data…
KOD
$44.74+2.08 (+4.88%)
Market OpenUpdated 2:16 PM EDT
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Kodiak Sciences Inc. in the Healthcare sector is trading at $43.88. The stock is currently near its 52-week high of $47.84, remaining 96.9% above its 200-day moving average. Technical signals show neutral RSI of 61 and bearish MACD signal, explaining why KOD maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$44.74
Potential Upside
5%
Whystock Fair Value$46.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular end...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.81B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-146.12%
Volume
Today's trading volume
143,546
Recent News
Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences Inc (KOD): What’s the Chance of Success for Zenkuda?
Kodiak Sciences Inc (NASDAQ:KOD) is among the best 52-week high US stocks to buy. On March 27, H.C. Wainwright boosted its price target on Kodiak Sciences Inc (NASDAQ:KOD) to $58 from $38 and reiterated a Buy rating on the shares. The firm raised its price target after positive Phase 3 GLOW2 trial results for tarcocimab […]
Eagle Eye Solutions Group Leads The Charge In UK Penny Stocks
The United Kingdom's market has recently faced challenges, with the FTSE 100 index experiencing a dip due to weak trade data from China, highlighting ongoing global economic uncertainties. Despite these broader market fluctuations, investors often look towards penny stocks for their potential to uncover growth opportunities in smaller or newer companies. While the term "penny stocks" might seem outdated, they remain a relevant investment area that can offer significant upside when backed by...
Kodiak Sciences (KOD) Reports Q4 EPS of ($1.05)
Kodiak Sciences Inc. (NASDAQ:KOD) is one of the 8 Healthcare Stocks Insiders Are Buying. On April 1, 2026, Kodiak Sciences Inc. (NASDAQ:KOD) reported Q4 EPS of ($1.05) compared to (84c) last year. Victor Perlroth, M.D., Chief Executive Officer, said momentum is building, citing “positive Phase 3 topline results” from the GLOW2 study and progress across […]
Kodiak Sciences GLOW2 Win Puts Zenkuda And Funding Needs In Focus
Kodiak Sciences (NasdaqGM:KOD) reported positive topline Phase 3 results from its GLOW2 study of Zenkuda (tarcocimab tedromer) for diabetic retinopathy. The company plans to accelerate regulatory submission for Zenkuda based on the reported safety and efficacy profile. This announcement marks a key clinical milestone for Kodiak Sciences and its lead ophthalmology candidate. Kodiak Sciences, trading at about $39.0, has seen very large 1 year and 3 year share price moves, with returns of...